Literature DB >> 26486358

Cryptococcal meningoencephalitis associated with the long-term use of ruxolitinib.

Chih-Cheng Chen, Yi-Yang Chen, Cih-En Huang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26486358     DOI： 10.1007/s00277-015-2532-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  10 in total

Review 1.  Fatal Disseminated Tuberculosis and Concurrent Disseminated Cryptococcosis in a Ruxolitinib-treated Patient with Primary Myelofibrosis: A Case Report and Literature Review.

Authors:  Asuka Ogai; Kazuma Yagi; Fumimaro Ito; Hideharu Domoto; Tetsuya Shiomi; Kenko Chin
Journal:  Intern Med       Date:  2021-09-25       Impact factor: 1.282

Review 2.  COVID-19-associated opportunistic infections: a snapshot on the current reports.

Authors:  Amir Abdoli; Shahab Falahi; Azra Kenarkoohi
Journal:  Clin Exp Med       Date:  2021-08-23       Impact factor: 5.057

3.  Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis.

Authors:  Douglas Tremblay; Amber King; Lihua Li; Erin Moshier; Alexander Coltoff; Anita Koshy; Marina Kremyanskaya; Ronald Hoffman; Michael J Mauro; Raajit K Rampal; John Mascarenhas
Journal:  Leuk Lymphoma       Date:  2019-11-12

4.  Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors.

Authors:  Marissa A Zarakas; Jigar V Desai; Georgios Chamilos; Michail S Lionakis
Journal:  Curr Fungal Infect Rep       Date:  2019-07-05

5.  Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.

Authors:  Palma Manduzio
Journal:  Ther Clin Risk Manag       Date:  2017-02-13       Impact factor: 2.423

6.  A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib.

Authors:  Katya Prakash; Douglas Richman
Journal:  BMC Infect Dis       Date:  2019-03-27       Impact factor: 3.090

Review 7.  Cryptococcal fungemia and Mycobacterium haemophilum cellulitis in a patient receiving ruxolitinib: a case report and literature review.

Authors:  Naruemit Sayabovorn; Piriyaporn Chongtrakool; Methee Chayakulkeeree
Journal:  BMC Infect Dis       Date:  2021-01-07       Impact factor: 3.090

8.  Cryptococcal infection with ruxolitinib in primary myelofibrosis: A case report and literature review.

Authors:  Zachary Ciochetto; Njeri Wainaina; Mary Beth Graham; Anna Corey; Muhammad Bilal Abid
Journal:  Clin Case Rep       Date:  2022-02-20

9.  Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis.

Authors:  Anna Hirano; Masahiro Yamasaki; Naomi Saito; Koji Iwato; Wakako Daido; Kunihiko Funaishi; Sayaka Ishiyama; Naoko Deguchi; Masaya Taniwaki; Nobuyuki Ohashi
Journal:  Respir Med Case Rep       Date:  2017-07-04

10.  A case report of cryptococcal meningitis associated with ruxolitinib.

Authors:  Daisuke Tsukui; Hiroaki Fujita; Keisuke Suzuki; Koichi Hirata
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.